

Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

Question: Should Ivermectin compared to Chloroquine be used for COVID-19 patients?

Setting: Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ivermectin	Chloroquine	Relative (95% CI)	Absolute (95% CI)	
All-cause mortality											
1	randomised trials	not serious	not serious	not serious	serious ^a	none	13/53 (24.5%)	13/61 (21.3%)	RR 1.15 (0.59 to 2.26)	32 more per 1.000 (from 87 fewer to 269 more)	⊕⊕⊕○ MODERATE
Progression of COVID-19 disease											
1	randomised trials	not serious	not serious	not serious	serious ^a	none	14/53 (26.4%)	12/61 (19.7%)	RR 1.34 (0.68 to 2.64)	67 more per 1.000 (from 63 fewer to 323 more)	⊕⊕⊕○ MODERATE
Number of patients with respiratory distress syndrome											
1	randomised trials	not serious	not serious	not serious	serious ^a	none	14/53 (26.4%)	13/61 (21.3%)	RR 1.24 (0.64 to 2.40)	51 more per 1.000 (from 77 fewer to 298 more)	⊕⊕⊕○ MODERATE

Explanations

a. Downgraded of one level for small sample size

References

1. Galan LEB, Santos NMD, Asato MS, Araújo JV, de Lima Moreira A, Marques Araújo AM, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. Pathog Glob Health. 2021 Mar 8:1-8. doi: 10.1080/20477724.2021.1890887. Epub ahead of print.